Colorectal Cancer Drugs Global Market Report 2023: Sector to Reach $16.22 Billion in 2027 at a CAGR of 3.3%

DUBLIN, March 7, 2023 /PRNewswire/ -- The "Colorectal Cancer Drugs Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the market.

The global colorectal cancer drugs market will grow from $13.65 billion in 2022 to $14.21 billion in 2023 at a compound annual growth rate (CAGR) of 4.1%. The colorectal cancer drugs market is expected to grow to $16.22 billion in 2027 at a CAGR of 3.3%.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Major players in the colorectal cancer drugs market are Merck & Co. Inc, Roche, Sanofi, Amgen, Pfizer Inc., Abbott Laboratories, Taiho Pharma, Novartis, GlaxoSmithKline, Onyx, TAKEDA PHARMACEUTICALS, Bristol-Myers Squib, Sumitomo Dainippon Pharma, Array BioPharma, Eli Lilly, RANDOX LABORATORIES, Suzhou Zelgen Biopharmaceuticals, Beckman Coulter Inc, Regeneron, EDP Biotech, Genomic Tree, Metabiomics Corporation, SIEMENS HEALTHCARE, Suzhou Zelgen Biopharmaceuticals, Sumitomo Dainippon Pharma and EPIGENOMICS.

The colorectal cancer drug market consists of sales of avastin, bevacizumab, and camptosar. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Colorectal cancer (CRC) or bowel cancer, is cancer affecting the large intestine and the rectum. They are also named, colon tumors or rectal cancer depending upon where they begin.

North America was the largest region in the colorectal cancer drugs market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of colorectal cancer drugs are vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, and programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators. Vascular endothelial growth factors (VEGF) are drugs that block VEGF and VEGFR activity. The various classes of drugs include immunotherapy, chemotherapy, and others that are distributed by hospitals pharmacies, retail pharmacies, and others.

The number of cases of colorectal cancer worldwide has been increasing. For instance, in March 2020, according to research published in ACS Publications, a US-based scientific journal, based on data from the National Center for Health Statistics, a total of 147,950 people would be diagnosed with CRC, and 53,200 would pass away from it. 17,930 of these cases and fatalities will be in people under the age of 50.

The number of diagnosed incident cases of colorectal cancer is expected to increase by 27.3% to 672,400 cases by 2037. The reason for this increase can be attributed to factors such as a low-fiber diet, obesity, and consumption of alcohol and tobacco, among others. The increase in the number of colorectal cancer cases will add to the overall size of the global colorectal cancer drug market.

The increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body's immune system to fight cancer rather than chemical drugs which reduces the body's immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV where chemical drugs are ineffective. For example, some targeted therapies that have been approved to treat colorectal cancer include bevacizumab, cetuximab, and panitumumab. The advantages of biological drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

Targeted therapies have already begun to extend the lifespan of metastatic Colorectal cancer patients compared with chemotherapy-only therapy. Target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells. Opdivo and Keytruda are examples of targeted therapies.

The colorectal cancer industry is governed by a regulatory framework laid down by agencies such as the US Food and Administration Agency (FDA), the European Medicines Agency (EMA), the American Society of Clinical Oncology (ASCO), and others. For instance, the FDA's recommendation for the colorectal cancer drugs industry in the form of guidelines is mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 312, which contains sub-parts from A to me.

The sub-part E deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening illnesses such as colorectal cancer. It also includes guidelines for the monitoring and evaluation of clinical trials of colorectal cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments.

The countries covered in the colorectal cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Key Topics Covered:

1. Executive Summary

2. Colorectal Cancer Drugs Market Characteristics

3. Colorectal Cancer Drugs Market Trends And Strategies

4. Colorectal Cancer Drugs Market - Macro Economic Scenario
4.1 COVID-19 Impact On Colorectal Cancer Drugs Market
4.2 Ukraine-Russia War Impact On Colorectal Cancer Drugs Market
4.3 Impact Of High Inflation On Colorectal Cancer Drugs Market

5. Colorectal Cancer Drugs Market Size And Growth
5.1. Global Colorectal Cancer Drugs Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Colorectal Cancer Drugs Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Colorectal Cancer Drugs Market Segmentation
6.1. Global Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Vascular Endothelial Growth Factor (VEGF) Inhibitors
• Epidermal Growth Factor Receptor (EGFR) Inhibitors
• Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
• BRAF or MEK Inhibitors
• Tyrosine Kinase (TKI) Inhibitors
• Immunomodulators

6.2. Global Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Hospitals Pharmacies
• Retail Pharmacies
• Other Distribution Channels

6.3. Global Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Immunotherapy
• Chemotherapy
• Others Class

7. Colorectal Cancer Drugs Market Regional And Country Analysis
7.1. Global Colorectal Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Colorectal Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/2w4cg5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets